Similar articles

• Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.

  Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J. Li S, et al. BMC Cancer. 2014 May 28;14:376. doi: 10.1186/1471-2407-14-376. BMC Cancer. 2014. PMID: 24886512 Free PMC article.
• Will mTOR inhibitors make it as cancer drugs?

  Sawyers CL. Sawyers CL. Cancer Cell. 2003 Nov;4(5):343-8. doi: 10.1016/s1535-6108(03)00275-7. Cancer Cell. 2003. PMID: 14667501 Review. No abstract available.
• Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

  Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ. Spunt SL, et al. J Clin Oncol. 2011 Jul 20;29(21):2933-40. doi: 10.1200/JCO.2010.33.4649. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690471 Free PMC article. Clinical Trial.
• [Antihormonal therapy in breast cancer and mTOR inhibitors].

  Heudel PÉ, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T. Heudel PÉ, et al. Bull Cancer. 2011 Dec;98(12):1431-7. doi: 10.1684/bdc.2011.1496. Bull Cancer. 2011. PMID: 22133994 French.
• New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

  Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. Albert S, et al. Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Expert Opin Investig Drugs. 2010. PMID: 20569080 Review.